Literature DB >> 9252708

Detection of occult liver metastases in colorectal cancer by measurement of biliary carcinoembryonic antigen.

F Novell1, M Trias, R Molina, X Filella.   

Abstract

About a 20-25% of the patients at diagnosis of colorectal carcinoma present with occult liver metastases. The aim of this work was to determine the prognostic significance of CEA bile level for the early detection of occult metastases. We determined the CEA blood level and the CEA bile level in 182 patients with colorectal carcinoma (3 Dukes' stage A, 86 Dukes' stage B, 53 Dukes' stage C, and 40 patients with liver metastases) and also in 42 patients with simple cholelithiasis, as the control group. In the patients with cholelithiasis, the mean values of CEA serum and bile levels were normal. In patients with colorectal carcinomas the CEA serum levels ranged from 3 to 110 ng/ml, and the CEA bile level from 3 to 226 ng/ml. Patients with liver metastases, had a mean CEA serum level of 193 ng/ml, while CEA bile level was 1,225 ng/ml. In conclusion, our results suggest that the determination of CEA bile is highly useful in the diagnosis of occult liver metastases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9252708

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Biliary carcinoembryonic antigen levels in diagnosis of occult hepatic metastases from colorectal carcinoma.

Authors:  Jaques Waisberg; Rogério T Palma; Luís Contim Neto; Lourdes C Martins; Maurício S L Oliveira; Carlos A Nagashima; Antonio C Godoy; Fabio S Goffi
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

2.  Intensive follow-up after liver resection for colorectal liver metastases: results of combined serial tumour marker estimations and computed tomography of the chest and abdomen - a prospective study.

Authors:  S Bhattacharjya; R Aggarwal; B R Davidson
Journal:  Br J Cancer       Date:  2006-07-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.